Integrated  ||| S:0 E:11 ||| NNP
analyses  ||| S:11 E:20 ||| NNS
of  ||| S:20 E:23 ||| IN
a  ||| S:23 E:25 ||| DT
major  ||| S:25 E:31 ||| JJ
histocompatibility  ||| S:31 E:50 ||| JJ
complex ||| S:50 E:57 ||| NN
,  ||| S:57 E:59 ||| ,
methylation  ||| S:59 E:71 ||| NN
and  ||| S:71 E:75 ||| CC
transcribed  ||| S:75 E:87 ||| JJ
ultra-conserved  ||| S:87 E:103 ||| JJ
regions  ||| S:103 E:111 ||| NNS
in  ||| S:111 E:114 ||| IN
systemic  ||| S:114 E:123 ||| FW
lupus  ||| S:123 E:129 ||| FW
erythematosus  ||| S:129 E:143 ||| FW
Systemic  ||| S:143 E:152 ||| FW
lupus  ||| S:152 E:158 ||| FW
erythematosus  ||| S:158 E:172 ||| FW
( ||| S:172 E:173 ||| -LRB-
SLE ||| S:173 E:176 ||| NNP
)  ||| S:176 E:178 ||| -RRB-
is  ||| S:178 E:181 ||| VBZ
a  ||| S:181 E:183 ||| DT
multifactorial  ||| S:183 E:198 ||| JJ
autoimmune  ||| S:198 E:209 ||| JJ
disease  ||| S:209 E:217 ||| NN
which  ||| S:217 E:223 ||| WDT
affects  ||| S:223 E:231 ||| VBZ
different  ||| S:231 E:241 ||| JJ
organs  ||| S:241 E:248 ||| NNS
and  ||| S:248 E:252 ||| CC
systems  ||| S:252 E:260 ||| NNS
that ||| S:260 E:264 ||| WDT
,  ||| S:264 E:266 ||| ,
has  ||| S:266 E:270 ||| VBZ
a  ||| S:270 E:272 ||| DT
complex  ||| S:272 E:280 ||| JJ
genetic  ||| S:280 E:288 ||| JJ
inheritance ||| S:288 E:299 ||| NN
,  ||| S:299 E:301 ||| ,
and  ||| S:301 E:305 ||| CC
is  ||| S:305 E:308 ||| VBZ
affected  ||| S:308 E:317 ||| VBN
by  ||| S:317 E:320 ||| IN
both  ||| S:320 E:325 ||| DT
epigenetic  ||| S:325 E:336 ||| NN
and  ||| S:336 E:340 ||| CC
environmental  ||| S:340 E:354 ||| JJ
risk  ||| S:354 E:359 ||| NN
factors ||| S:359 E:366 ||| NNS
.  ||| S:366 E:368 ||| .
Previous  ||| S:368 E:377 ||| JJ
studies  ||| S:377 E:385 ||| NNS
on  ||| S:385 E:388 ||| IN
SLE  ||| S:388 E:392 ||| NNP
have  ||| S:392 E:397 ||| VBP
lacked  ||| S:397 E:404 ||| VBN
the  ||| S:404 E:408 ||| DT
statistical  ||| S:408 E:420 ||| JJ
power  ||| S:420 E:426 ||| NN
and  ||| S:426 E:430 ||| CC
genetic  ||| S:430 E:438 ||| JJ
resolution  ||| S:438 E:449 ||| NN
to  ||| S:449 E:452 ||| TO
fully  ||| S:452 E:458 ||| RB
determine  ||| S:458 E:468 ||| VB
the  ||| S:468 E:472 ||| DT
influence  ||| S:472 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
major  ||| S:485 E:491 ||| JJ
histocompatibility  ||| S:491 E:510 ||| JJ
complex  ||| S:510 E:518 ||| NNP
( ||| S:518 E:519 ||| -LRB-
MHC ||| S:519 E:522 ||| NNP
)  ||| S:522 E:524 ||| -RRB-
on  ||| S:524 E:527 ||| IN
SLE ||| S:527 E:530 ||| NNP
.  ||| S:530 E:532 ||| .
In  ||| S:532 E:535 ||| IN
this  ||| S:535 E:540 ||| DT
study ||| S:540 E:545 ||| NN
,  ||| S:545 E:547 ||| ,
in  ||| S:547 E:550 ||| IN
order  ||| S:550 E:556 ||| NN
to  ||| S:556 E:559 ||| TO
determine  ||| S:559 E:569 ||| VB
this  ||| S:569 E:574 ||| DT
influence ||| S:574 E:583 ||| NN
,  ||| S:583 E:585 ||| ,
a  ||| S:585 E:587 ||| DT
total  ||| S:587 E:593 ||| NN
of  ||| S:593 E:596 ||| IN
15 patients  ||| S:596 E:608 ||| CD
with  ||| S:608 E:613 ||| IN
SLE  ||| S:613 E:617 ||| NNP
and  ||| S:617 E:621 ||| CC
15 healthy  ||| S:621 E:632 ||| CD
controls  ||| S:632 E:641 ||| NNS
were  ||| S:641 E:646 ||| VBD
enrolled ||| S:646 E:654 ||| VBN
.  ||| S:654 E:656 ||| .
MHC  ||| S:656 E:660 ||| NNP
region  ||| S:660 E:667 ||| NN
capture  ||| S:667 E:675 ||| NN
technology ||| S:675 E:685 ||| NN
,  ||| S:685 E:687 ||| ,
hMeDIP-chip ||| S:687 E:698 ||| NNP
,  ||| S:698 E:700 ||| ,
transcribed  ||| S:700 E:712 ||| FW
ultra-conserved  ||| S:712 E:728 ||| FW
region  ||| S:728 E:735 ||| FW
( ||| S:735 E:736 ||| -LRB-
T-UCR ||| S:736 E:741 ||| NNP
)  ||| S:741 E:743 ||| -RRB-
microarray  ||| S:743 E:754 ||| NN
and  ||| S:754 E:758 ||| CC
bioinformatics  ||| S:758 E:773 ||| JJ
analysis  ||| S:773 E:782 ||| NN
were  ||| S:782 E:787 ||| VBD
utilized  ||| S:787 E:796 ||| VBN
for  ||| S:796 E:800 ||| IN
both  ||| S:800 E:805 ||| DT
groups ||| S:805 E:811 ||| NNS
.  ||| S:811 E:813 ||| .
The  ||| S:813 E:817 ||| DT
results  ||| S:817 E:825 ||| NNS
revealed  ||| S:825 E:834 ||| VBD
methylated  ||| S:834 E:845 ||| JJ
CpG  ||| S:845 E:849 ||| JJ
enrichment  ||| S:849 E:860 ||| NN
at  ||| S:860 E:863 ||| IN
6 loci  ||| S:863 E:870 ||| CD
in  ||| S:870 E:873 ||| IN
the  ||| S:873 E:877 ||| DT
MHC  ||| S:877 E:881 ||| NNP
segment  ||| S:881 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
SLE ||| S:892 E:895 ||| NNP
.  ||| S:895 E:897 ||| .
We  ||| S:897 E:900 ||| PRP
found  ||| S:900 E:906 ||| VBD
4 single-nucleotide  ||| S:906 E:926 ||| CD
polymorphisms  ||| S:926 E:940 ||| CD
( ||| S:940 E:941 ||| -LRB-
SNPs ||| S:941 E:945 ||| NNP
)  ||| S:945 E:947 ||| -RRB-
in  ||| S:947 E:950 ||| IN
the  ||| S:950 E:954 ||| DT
CpG  ||| S:954 E:958 ||| JJ
promoter  ||| S:958 E:967 ||| NN
of  ||| S:967 E:970 ||| IN
human  ||| S:970 E:976 ||| JJ
leukocyte  ||| S:976 E:986 ||| JJ
antigen-B  ||| S:986 E:996 ||| NNP
( ||| S:996 E:997 ||| -LRB-
HLA-B ||| S:997 E:1002 ||| NNP
)  ||| S:1002 E:1004 ||| -RRB-
and  ||| S:1004 E:1008 ||| CC
2 SNPs  ||| S:1008 E:1015 ||| CD
in  ||| S:1015 E:1018 ||| IN
chr6 ||| S:1018 E:1022 ||| CD
: ||| S:1022 E:1023 ||| :
29521110‑29521833 ||| S:1023 E:1040 ||| CD
.  ||| S:1040 E:1042 ||| .
No  ||| S:1042 E:1045 ||| DT
significant  ||| S:1045 E:1057 ||| JJ
GO  ||| S:1057 E:1060 ||| NNP
term  ||| S:1060 E:1065 ||| NN
or  ||| S:1065 E:1068 ||| CC
KEGG  ||| S:1068 E:1073 ||| NNP
pathway  ||| S:1073 E:1081 ||| NN
enrichment  ||| S:1081 E:1092 ||| NNS
was  ||| S:1092 E:1096 ||| VBD
noted  ||| S:1096 E:1102 ||| VBN
for  ||| S:1102 E:1106 ||| IN
an  ||| S:1106 E:1109 ||| DT
immune-correlated  ||| S:1109 E:1127 ||| JJ
process  ||| S:1127 E:1135 ||| NN
in  ||| S:1135 E:1138 ||| IN
the  ||| S:1138 E:1142 ||| DT
SLE  ||| S:1142 E:1146 ||| NNP
patients  ||| S:1146 E:1155 ||| NNS
for  ||| S:1155 E:1159 ||| IN
the  ||| S:1159 E:1163 ||| DT
corresponding  ||| S:1163 E:1177 ||| JJ
CpG-methylated  ||| S:1177 E:1192 ||| JJ
genes ||| S:1192 E:1197 ||| NNS
.  ||| S:1197 E:1199 ||| .
In  ||| S:1199 E:1202 ||| IN
this  ||| S:1202 E:1207 ||| DT
study ||| S:1207 E:1212 ||| NN
,  ||| S:1212 E:1214 ||| ,
T-UCR  ||| S:1214 E:1220 ||| NNP
was  ||| S:1220 E:1224 ||| VBD
not  ||| S:1224 E:1228 ||| RB
discovered  ||| S:1228 E:1239 ||| VBN
in  ||| S:1239 E:1242 ||| IN
the  ||| S:1242 E:1246 ||| DT
MHC  ||| S:1246 E:1250 ||| NNP
segment ||| S:1250 E:1257 ||| NN
.  ||| S:1257 E:1259 ||| .
The  ||| S:1259 E:1263 ||| DT
analysis  ||| S:1263 E:1272 ||| NN
of  ||| S:1272 E:1275 ||| IN
SNPs  ||| S:1275 E:1280 ||| NNP
( ||| S:1280 E:1281 ||| -LRB-
rs1050683 ||| S:1281 E:1290 ||| NNP
,  ||| S:1290 E:1292 ||| ,
rs12697943 ||| S:1292 E:1302 ||| NNP
,  ||| S:1302 E:1304 ||| ,
rs17881210 ||| S:1304 E:1314 ||| NNP
,  ||| S:1314 E:1316 ||| ,
rs1065378 ||| S:1316 E:1325 ||| NNP
,  ||| S:1325 E:1327 ||| ,
rs17184255  ||| S:1327 E:1338 ||| NNP
and  ||| S:1338 E:1342 ||| CC
rs16895070 ||| S:1342 E:1352 ||| CD
)  ||| S:1352 E:1354 ||| -RRB-
and  ||| S:1354 E:1358 ||| CC
gene  ||| S:1358 E:1363 ||| NN
expression  ||| S:1363 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
peripheral  ||| S:1377 E:1388 ||| JJ
blood  ||| S:1388 E:1394 ||| NN
lymphocytes  ||| S:1394 E:1406 ||| VBZ
indicated  ||| S:1406 E:1416 ||| VBN
that  ||| S:1416 E:1421 ||| IN
these  ||| S:1421 E:1427 ||| DT
SNPs  ||| S:1427 E:1432 ||| NN
were  ||| S:1432 E:1437 ||| VBD
associated  ||| S:1437 E:1448 ||| VBN
with  ||| S:1448 E:1453 ||| IN
the  ||| S:1453 E:1457 ||| DT
occurrence  ||| S:1457 E:1468 ||| NN
of  ||| S:1468 E:1471 ||| IN
SLE ||| S:1471 E:1474 ||| NNP
.  ||| S:1474 E:1476 ||| .
Further  ||| S:1476 E:1484 ||| JJ
studies  ||| S:1484 E:1492 ||| NNS
are  ||| S:1492 E:1496 ||| VBP
warranted  ||| S:1496 E:1506 ||| VBN
to  ||| S:1506 E:1509 ||| TO
examine  ||| S:1509 E:1517 ||| VB
the  ||| S:1517 E:1521 ||| DT
roles  ||| S:1521 E:1527 ||| NNS
of  ||| S:1527 E:1530 ||| IN
these  ||| S:1530 E:1536 ||| DT
SNPs  ||| S:1536 E:1541 ||| JJ
in  ||| S:1541 E:1544 ||| IN
the  ||| S:1544 E:1548 ||| DT
pathogenesis  ||| S:1548 E:1561 ||| NN
of  ||| S:1561 E:1564 ||| IN
SLE ||| S:1564 E:1567 ||| NNP
.  ||| S:1567 E:1569 ||| .
Integrative  ||| S:1569 E:1581 ||| JJ
analysis  ||| S:1581 E:1590 ||| NN
technology  ||| S:1590 E:1601 ||| NN
provided  ||| S:1601 E:1610 ||| VBD
a  ||| S:1610 E:1612 ||| DT
view  ||| S:1612 E:1617 ||| NN
of  ||| S:1617 E:1620 ||| IN
the  ||| S:1620 E:1624 ||| DT
molecular  ||| S:1624 E:1634 ||| JJ
signaling  ||| S:1634 E:1644 ||| JJ
pathways  ||| S:1644 E:1653 ||| NN
in  ||| S:1653 E:1656 ||| IN
SLE ||| S:1656 E:1659 ||| NNP
.  ||| S:1659 E:1661 ||| .
